Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.69 |
| ▸ | PPARA | Q07869 | 8/20 | 0.69 |
| ▸ | PPARD | Q03181 | 3/20 | 0.69 |
| ▸ | ADAMTS5 | Q9UNA0 | 6/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3964579 | 1.00 | PPARG (0.69) | PPARGPPARAPPARDADAMTS5HPGD | |
| SCHEMBL9272176 | 0.84 | ADAMTS5 (0.78) | ADAMTS5HPGDKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL3965041 | 0.84 | PPARG (0.51) | PPARGPPARAPPARDHPGDKMT2A | |
| SCHEMBL3965050 | 0.84 | PPARG (0.51) | PPARGPPARAPPARDHPGDKMT2A | |
| SCHEMBL5390699 | 0.83 | PPARG (0.92) | PPARGPPARAPPARD | |
| SCHEMBL5379993 | 0.83 | PPARG (0.92) | PPARGPPARAPPARD | |
| SCHEMBL3959712 | 0.83 | ADAMTS5 (0.58) | PPARGPPARAPPARDADAMTS5KMT2A | |
| SCHEMBL6148812 | 0.83 | PTPN1 (0.68) | PPARGPPARAPPARDHPGDKMT2A | |
| SCHEMBL9273628 | 0.83 | KMT2A (0.82) | ADAMTS5HPGDKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL5375709 | 0.82 | PPARG (0.73) | PPARGPPARAPPARDSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.